stockrow
Friday 6 November 2026
Export SHPH’s income statement to Excel — free account
Shuttle Pharmaceuticals Holdings, Inc.
SHPH Healthcare Drug Manufacturers Specialty & Generic
- EPS
- +90.6%
- Free cash flow
- +82.0%
Quarter to June 2026, against a year earlier
5.22
0.18
+3.57%
Follow SHPH
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Gross margin, % | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | 0 | (1) | — | (1) | (1) | (5) | (7) | (9) | (12) | (10) | +65.0% | ||||||
| EBT margin, % | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (1) | — | (1) | (1) | (5) | (7) | (9) | (12) | (10) | +65.0% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | (0.02) | (0.05) | — | (0.07) | (247.72) | (1,260.92) | (880.00) | (797.50) | (71.60) | (27.27) | +178.1% | ||||||
| Cash flow | — | (0.01) | (0.04) | — | 0.00 | (63.89) | (498.30) | (744.15) | (637.15) | (57.89) | (6.49) | +181.0% | ||||||
| Capex | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | (2.53) | 0.00 | (18.66) | (0.08) | n/m | ||||||
| Free cash flow | — | (0.01) | (0.04) | — | 0.00 | (63.89) | (498.30) | (746.68) | (637.15) | (76.55) | (6.57) | +191.0% | ||||||
| Book value | — | (0.02) | 0.00 | — | (0.12) | (346.40) | 1,434.85 | 540.77 | 61.67 | 13.76 | 18.90 | n/m | ||||||
| Shares, m | — | 14 | 14 | — | 14 | 0 | 0 | 0 | 0 | 0 | 1 | (42.4%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | (1) | — | 0 | 0 | (3) | (6) | (7) | (9) | (7) | +61.7% | |||||
| Capex | — | — | — | — | 0 | — | — | 0 | — | (3) | 0 | +209.3% | ||||||
| Free cash flow | — | 0 | (1) | — | 0 | 0 | (3) | (6) | (7) | (13) | (7) | +67.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | 0 | 0 | — | (2) | (2) | 8 | 5 | 1 | (7) | (3) | +49.3% | |||||
| Net debt | — | 0 | 0 | — | 1 | 0 | (8) | (5) | (2) | 0 | 0 | n/m | ||||||
| Shareholders’ equity | — | 0 | 0 | — | (2) | (2) | 8 | 4 | 1 | 2 | 19 | n/m | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | 0.00 | (168.62) | — | (155.98) | (209.97) | (145.02) | (90.28) | (216.24) | (180.58) | (72.47) | (180.6) pt | |||||
| ROIC | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (387.84) | (36.73) | (387.8) pt | ||||||
| ROE | — | 0.00 | 487.62 | — | 109.31 | 75.65 | (223.05) | (112.37) | (383.83) | (791.04) | (90.05) | (791.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | 5 | 7 | 8 | 9 | 2 | — | (20.5%) | |||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Shuttle Pharmaceuticals Holdings, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZYBT Zhengye Biotechnology Holding Limited | $41.0M | — | — | — | — | −69.31% (below 0%: shrinking) | — | — | Compare |
| INCR InterCure Ltd. | $39.1M | 6.2× | — (loss-making) | −6.53% (below 0%: shrinking) | n/m | +389.50% (above 0%: growing) | 32.04% | 0.00% | Compare |
| SCYX SCYNEXIS, Inc. | $32.8M | — (loss-making) | — (loss-making) | −8.56% (below 0%: shrinking) | n/m | −98.60% (below 0%: shrinking) | 100.00% | (3,308.51%) | Compare |
| RMTI Rockwell Medical, Inc. | $30.6M | — (loss-making) | — (loss-making) | +10.63% (above 0%: growing) | n/m | −12.92% (below 0%: shrinking) | 18.24% | (5.97%) | Compare |
| IXHL Incannex Healthcare Inc. | $28.5M | — (loss-making) | — (loss-making) | −92.31% (below 0%: shrinking) | n/m | +327.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $24.0M | — (loss-making) | — | — | n/m | +82.01% (above 0%: growing) | 0.00% | 0.00% | |
| CPHI China Pharma Holdings, Inc. | $22.8M | — (loss-making) | — (loss-making) | −7.56% (below 0%: shrinking) | n/m | −113.57% (below 0%: shrinking) | 8.82% | (150.99%) | Compare |
| TXMD TherapeuticsMD, Inc. | $19.8M | — (loss-making) | 18.9× | −8.72% (below 0%: shrinking) | −80.00% (below 0%: shrinking) | +104.46% (above 0%: growing) | 100.00% | (93.90%) | Compare |
| AYTU Aytu BioPharma, Inc. | $19.7M | — (loss-making) | — (loss-making) | +6.42% (above 0%: growing) | n/m | +57.72% (above 0%: growing) | 64.63% | (4.82%) | Compare |
| Median of peers | $29.6M | — | — | −7.56% | — | +22.40% | 64.63% | (5.97%) |